Business Context and Reporting Period
Company: Genmab A/S
Filing Type: Form 6-K (Interim Report)
Reporting Period: Six months ended June 30, 2025
Currency Change: Effective January 1, 2025, Genmab changed its functional and presentation currency from DKK to USD. Prior period figures have been restated retrospectively.
Key Financial Metrics
| Metric (USD Million) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $1,640 | $1,382 |
| Operating Profit | $548 | $352 |
| Net Profit | $531 | $395 |
| Operating Margin | 33.4% | 25.5% |
| Net Profit Margin | 32.4% | 28.6% |
| Cash and Cash Equivalents | $1,296 | $622 |
| Marketable Securities | $1,603 | $1,637 |
| Total Assets | $6,464 | $5,544 |
| Shareholders' Equity | $5,302 | $4,445 |
| Net Cash from Operating Activities | $349 | $438 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 19% ($258 million) driven by higher royalties from DARZALEX (J&J) and Kesimpta (Novartis), and increased net product sales of EPKINLY.
- Royalty Performance: Royalty revenue rose 24% to $1,378 million. DARZALEX royalties increased 23% ($1,088 million) and Kesimpta royalties increased 38% ($198 million).
- Operating Expenses: Total costs and operating expenses increased 6% to $1,092 million, primarily due to pipeline expansion (Rina-S), organizational growth, and profit-sharing payments to AbbVie related to EPKINLY sales.
- Financial Items: Net financial income decreased to $119 million (from $204 million) due to lower interest income from reduced cash balances and reduced foreign exchange impacts following the currency change.
- Acquisition Impact: The 2024 acquisition of ProfoundBio contributed to R&D expenses and intangible assets but no acquisition-related charges were recorded in H1 2025.
Guidance, Outlook, and Risks
2025 Full Year Guidance (Revised)
- Revenue: $3.5 - $3.7 billion (Mid-point: $3.6 billion), up from previous guidance of $3.34 - $3.66 billion.
- Operating Profit: $1.055 - $1.405 billion (Mid-point: $1.23 billion), up from previous guidance of $0.895 - $1.365 billion.
- Drivers: Improved guidance is primarily driven by higher projected royalty revenues from DARZALEX.
Management Commentary & Pipeline
- EPKINLY: Submitted a supplemental Biologics License Application (sBLA) to the FDA for epcoritamab plus R2 in relapsed/refractory follicular lymphoma (FL). Launched Tivdak in Japan.
- Rina-S: Encouraging antitumor activity data presented at ASCO 2025 for endometrial cancer; additional Phase 3 trials announced.
- Commercialization: Continued expansion of commercial capabilities for EPKINLY and Rina-S.
Risks and Contingencies
- Legal: Chugai filed a patent infringement lawsuit in Japan regarding EPKINLY; Genmab is vigorously defending. AbbVie filed a trade secret complaint in the U.S. regarding Rina-S; Genmab refutes allegations.
- Regulatory: Risks related to FDA review delays and evolving trade policies/tariffs.
Investor Verification Checklist
- Currency Restatement: Verify that all prior period comparisons are adjusted for the DKK to USD functional currency change effective Jan 1, 2025.
- Royalty Dependencies: Confirm the sensitivity of revenue guidance to J&J's DARZALEX net sales estimates ($13.7 - $14.1 billion projected for 2025).
- Legal Exposure: Monitor the status of the Chugai patent litigation in Japan and the AbbVie trade secret complaint in the U.S. for potential financial provisions.
- Profit Sharing: Review the impact of profit-sharing payments to AbbVie on EPKINLY margins as sales scale.
- Capital Allocation: Note the $430 million share repurchase program executed in H1 2025 and its impact on cash reserves.